TW202132269A - 登革熱疾病及治療和預防 - Google Patents

登革熱疾病及治療和預防 Download PDF

Info

Publication number
TW202132269A
TW202132269A TW109139793A TW109139793A TW202132269A TW 202132269 A TW202132269 A TW 202132269A TW 109139793 A TW109139793 A TW 109139793A TW 109139793 A TW109139793 A TW 109139793A TW 202132269 A TW202132269 A TW 202132269A
Authority
TW
Taiwan
Prior art keywords
compound
log
copies
series
dengue
Prior art date
Application number
TW109139793A
Other languages
English (en)
Chinese (zh)
Inventor
奧利維亞 哥特士
巴特 凱斯特琳
巴特 史塔普
尚 弗朗索瓦 邦汎帝
提姆 瓊克斯
馬尼克斯 汎洛克
蘇珊 卡普汀
約翰 內斯
Original Assignee
美商健生醫藥公司
天主教魯汶大學
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商健生醫藥公司, 天主教魯汶大學 filed Critical 美商健生醫藥公司
Publication of TW202132269A publication Critical patent/TW202132269A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW109139793A 2019-11-15 2020-11-13 登革熱疾病及治療和預防 TW202132269A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP19209593.3 2019-11-15
EP19209593 2019-11-15
EP19213851.9 2019-12-05
EP19213851 2019-12-05
EP20171172 2020-04-23
EP20171172.8 2020-04-23

Publications (1)

Publication Number Publication Date
TW202132269A true TW202132269A (zh) 2021-09-01

Family

ID=73288639

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109139793A TW202132269A (zh) 2019-11-15 2020-11-13 登革熱疾病及治療和預防

Country Status (14)

Country Link
US (1) US12702657B2 (cg-RX-API-DMAC7.html)
EP (1) EP4058019A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023502053A (cg-RX-API-DMAC7.html)
KR (1) KR20220101679A (cg-RX-API-DMAC7.html)
CN (1) CN114980884A (cg-RX-API-DMAC7.html)
AU (1) AU2020382911A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022009199A2 (cg-RX-API-DMAC7.html)
CA (1) CA3161338A1 (cg-RX-API-DMAC7.html)
IL (1) IL292970A (cg-RX-API-DMAC7.html)
MX (1) MX2022005879A (cg-RX-API-DMAC7.html)
PH (1) PH12022551160A1 (cg-RX-API-DMAC7.html)
TW (1) TW202132269A (cg-RX-API-DMAC7.html)
UA (1) UA129409C2 (cg-RX-API-DMAC7.html)
WO (1) WO2021094563A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119173261A (zh) * 2022-05-12 2024-12-20 杨森制药公司 登革热病毒感染的治疗和/或预防
WO2025248536A1 (en) * 2024-05-29 2025-12-04 Zydus Lifesciences Limited Novel oxime derivatives to treat viral infections
WO2025253267A1 (en) 2024-06-06 2025-12-11 Janssen Pharmaceuticals, Inc. Combination of mosnodenvir and close analogs with nitd-688 for use in the treatment and prevention of dengue disease

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1200899A (en) 1997-10-27 1999-05-17 Eli Lilly And Company Morpholino-n-ethyl ester prodrugs of indole spla2 inhibitors
EP1261610A2 (en) 2000-02-17 2002-12-04 Bristol-Myers Squibb Pharma Company Succinoylamino carbocycles and heterocycles as inhibitors of a-beta protein production
GB0110832D0 (en) 2001-05-03 2001-06-27 Virogen Ltd Antiviral compounds
EP1519735A4 (en) 2001-12-12 2006-01-11 Conforma Therapeutic Corp ASSAYS AND DEVICES FOR DETERMINING AND MODULATING HSP90 BINDING ACTIVITY
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
EP1749007A2 (en) 2004-03-30 2007-02-07 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
NZ555142A (en) 2004-12-23 2010-03-26 Novartis Ag Compounds for flaviviridae treatment
CN101103026A (zh) 2005-01-14 2008-01-09 健亚生物科技公司 用于治疗病毒感染的吲哚衍生物
AU2006221080A1 (en) 2005-02-09 2006-09-14 Migenix Inc. Compositions and methods for treating or preventing flaviviridae infections
DE102005028845A1 (de) 2005-06-22 2006-12-28 Sanofi-Aventis Deutschland Gmbh Substituierte Heterocyclen, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen
WO2007017093A1 (en) 2005-08-04 2007-02-15 Bayer Healthcare Ag Substituted 2-benzyloxy-benzoic acid amide derivatives
CN101253152A (zh) 2005-09-02 2008-08-27 安斯泰来制药株式会社 作为rock抑制剂的酰胺衍生物
FR2928645A1 (fr) 2008-03-14 2009-09-18 Sanofi Aventis Sa Nouveaux derives de carbazole inhibiteurs d'hsp90, compositions les contenant et utilisation
CN102056483A (zh) 2008-06-03 2011-05-11 西佳技术公司 用于治疗或预防登革病毒感染的小分子抑制剂
MX2011001872A (es) 2008-08-18 2011-05-23 Univ Yale Moduladores de mif.
EP2331499B1 (en) 2008-08-19 2016-09-21 Janssen Pharmaceutica NV Cold menthol receptor antagonists
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶,其組合物及使用其之治療方法
WO2010091413A1 (en) 2009-02-09 2010-08-12 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
US8993604B2 (en) 2009-06-30 2015-03-31 Siga Technologies, Inc. Treatment and prevention of dengue virus infections
CA2771124C (en) 2009-09-09 2019-01-15 Gilead Sciences, Inc. Inhibitors of flaviviridae viruses
EA201290575A1 (ru) 2010-01-15 2013-01-30 Джилид Сайэнс, Инк. Ингибиторы вирусов flaviviridae
WO2011120025A1 (en) 2010-03-26 2011-09-29 Glaxo Group Limited Indazolyl-pyrimidines as kinase inhibitors
JP5716205B2 (ja) 2011-03-29 2015-05-13 学校法人日本大学 グルコシダーゼ活性阻害用組成物及びそのスクリーニング方法
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
GB201305376D0 (en) 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
MX368158B (es) 2013-10-23 2019-09-20 Janssen Sciences Ireland Uc Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
JP6505727B2 (ja) 2014-01-31 2019-04-24 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company ヘテロ環式p2’基を有する第xia因子阻害剤としてのマクロ環
KR102382905B1 (ko) 2014-06-04 2022-04-04 프레드 헛친슨 켄서 리서치 센터 노치 1 및/또는 노치 2 작용제를 사용한 줄기 세포의 확장 및 생착
KR102391259B1 (ko) 2014-06-04 2022-04-26 암젠 인크 포유류 세포 배양물을 회수하는 방법
BR112017006708A2 (pt) 2014-10-01 2017-12-26 Janssen Pharmaceuticals Inc indóis mono- ou dissubstituídos como inibidores da replicação viral de dengue
US9944598B2 (en) 2014-10-01 2018-04-17 Janssen Pharmaceuticals, Inc. Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
NO2721243T3 (cg-RX-API-DMAC7.html) 2014-10-01 2018-10-20
ES2896198T3 (es) 2014-10-10 2022-02-24 Univ Rutgers Cebadores y sondas de reacción en cadena de polimerasa para Mycobacterium tuberculosis
PH12017501272B1 (en) 2015-01-16 2023-01-11 Janssen Pharmaceuticals Inc Indole derivatives as dengue viral replication inhibitors
AR103680A1 (es) 2015-02-23 2017-05-24 Lilly Co Eli Inhibidores selectivos de bace1
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JP6636133B2 (ja) 2015-07-22 2020-01-29 オメイコス セラピューティクス ゲーエムベーハー 心疾患の治療に対するcyp−エイコサノイドの代謝的にロバストな類縁体
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CA3002214C (en) 2015-11-03 2022-01-04 Zoetis Services Llc Sol-gel polymer composites and uses thereof
EP3433274A1 (en) 2016-03-25 2019-01-30 Visterra, Inc. Formulation of antibody molecules to dengue virus
WO2017167953A1 (en) 2016-03-31 2017-10-05 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
HRP20210847T1 (hr) 2016-03-31 2021-07-23 Janssen Pharmaceuticals, Inc. Supstituirani derivati indola kao inhibitori replikacije denga virusa
UY37174A (es) 2016-03-31 2017-10-31 Takeda Pharmaceuticals Co Un compuesto heterocíclico que tiene una acción inhibidora de monoacilglicerol lipasa
AU2017240801A1 (en) 2016-04-01 2018-10-25 Amgen Inc. Chimeric receptors to FLT3 and methods of use thereof
KR102427334B1 (ko) 2016-04-01 2022-08-03 카이트 파마 인코포레이티드 키메라 항원 및 t 세포 수용체 및 사용 방법
US10576085B2 (en) 2016-04-01 2020-03-03 Signal Pharmaceuticals, Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
EA201892200A1 (ru) 2016-04-01 2019-03-29 Янссен Фармасьютикалз, Инк. Замещенные производные соединений индола в качестве ингибиторов репликации вирусов денге
SG10201912519VA (en) 2016-04-01 2020-02-27 Kite Pharma Inc Chimeric receptors and methods of use thereof
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
MX2018012016A (es) 2016-04-01 2019-01-24 Basf Se Compuestos biciclicos.
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CR20190531A (es) 2017-05-22 2020-03-05 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CA3060583C (en) 2017-05-22 2024-06-04 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors

Also Published As

Publication number Publication date
EP4058019A1 (en) 2022-09-21
UA129409C2 (uk) 2025-04-16
US12702657B2 (en) 2026-08-11
MX2022005879A (es) 2022-06-14
KR20220101679A (ko) 2022-07-19
IL292970A (en) 2022-07-01
AU2020382911A1 (en) 2022-06-30
CN114980884A (zh) 2022-08-30
JP2023502053A (ja) 2023-01-20
CA3161338A1 (en) 2021-05-20
WO2021094563A1 (en) 2021-05-20
PH12022551160A1 (en) 2023-09-25
BR112022009199A2 (pt) 2022-07-26
US20220409583A1 (en) 2022-12-29

Similar Documents

Publication Publication Date Title
US20240269125A1 (en) Methods of treating coronavirus infections by co-administering an fkbp ligand and an antiviral agent
CN105636589B (zh) 脱氧野尻霉素衍生物及其使用方法
KR20220101679A (ko) 뎅기열 질환의 치료 및 예방
CN109789147B (zh) 用于治疗非酒精性脂肪性肝病的药物组合物及方法
EP4129290B1 (en) Pharmaceutical composition comprising pyronaridine or a salt thereof, artemisinin or a derivative thereof or a combination of both for preventing or treating a respiratory disease caused by a coronavirus
RU2518314C2 (ru) Способ и средство активации irf-3 для лечения и профилактики заболеваний, вызываемых (+) phk-содержащими вирусами
JP2001072585A (ja) ウイルス性心筋炎の予防または治療薬剤
CN116940360B (zh) 5-硝基-8-羟基喹啉的应用
WO2014169355A1 (en) Method of viral inhibition
EA049504B1 (ru) Лечение и профилактика лихорадки денге
HK40074715A (en) Treatment and prevention of dengue disease
WO2023070058A1 (en) Treatment of viruses with antiviral nucleosides
CN113440527B (zh) 萘酚喹或含萘酚喹的组合制剂在抗冠状病毒中的应用
US20210186976A1 (en) Methods and compositions for treatment of zika virus infection
CN102335171A (zh) 一类n-(2-噻唑)苯甲酰胺衍生物的应用
RU2843665C1 (ru) Фармацевтическая композиция для профилактики или лечения эпидемического рнк-вирусного инфекционного заболевания
EP4403177A1 (en) New combination drug for treating coronavirus infections, pharmaceutical composition and use thereof
EP3960173B1 (en) Enterovirus inhibitor
CN106727574A (zh) 马尼地平在制备治疗黄病毒科病毒感染药物中的应用
WO2017202789A1 (en) Methods and pharmaceutical compositions for the treatment of filovirus infections
Yang et al. Norovirus: Clinical Findings and Pharmaceutical Developments
WO2025133697A2 (en) Combination therapy for inhibition of ebolavirus
CN121466087A (zh) Pha-767491在制备防治h1n1亚型猪流感药物中的应用
EA025610B1 (ru) Антивирусная композиция и ее применение
KR20250002212A (ko) 인플루엔자 및 폭스바이러스 바이러스 감염을 치료하는 방법